Yaacov-Garbeli Dana 4

What Happened Yaacov-Garbeli Dana, Chief Financial Officer of Entera Bio Ltd. (ENTX), was granted 58,394 stock-settled restricted stock units (RSUs) on May 7, 2026. The RSUs were awarded in lieu of a cash bonus and were granted at a $0.00 per-share acquisition price (total reported value $0). The RSUs vest ratably quarterly over a one-year period beginning May 1, 2026.

Key Details

• Transaction type: Award/Grant (Code A) on 2026-05-07; filing dated 2026-05-08.
• Amount: 58,394 RSUs granted; acquisition price reported as $0.00 (no cash paid).
• Vesting: Ratably each quarter over one year starting May 1, 2026.
• Shares owned after transaction: Not specified in the provided excerpt of the filing.
• Additional note: Footnote states the grant was approved by the Board and awarded in lieu of a cash bonus.
• Ownership disclosure: Footnote indicates the reporting person owns a 33.33% interest in A2Z Counseling Ltd., which holds certain Entera shares; the reporting person disclaims beneficial ownership of those A2Z-held securities except for any pecuniary interest.
• Timeliness: Filed the day after the reported transaction date; not indicated as late.

Context

• These RSUs are compensation, not an open-market purchase or sale; they convert into shares as they vest, so they do not signal an immediate buy or sell.
• For retail investors, awards like this reflect standard compensation practices and should be viewed differently from open-market insider purchases or sales.